NEW YORK, Sept. 28 /PRNewswire/ — Delcath Systems, Inc.
DCTH) announced today that management will present at the
William Blair Emerging Growth Stock Conference on Tuesday, October
5, 2010 at 8:45 a.m. ET in New York, NY. Mr. David McDonald, Chief
Financial Officer, will provide an overview of the Company’s
business strategy and recent corporate developments.
Attendance at this conference is by invitation only. Delcath
will offer a live audio webcast of its presentation, which may be
accessed on the Investor Relations section of the Company’s website
at www.delcath.com. An archived
replay of the presentation will be available for 90 days, also at
About Delcath Systems
Delcath Systems, Inc. is a development stage, specialty
pharmaceutical and medical device company focused on oncology.
Delcath’s proprietary system for chemosaturation is designed to
administer high dose chemotherapy and other therapeutic agents to
diseased organs or regions of the body, while controlling the
systemic exposure of those agents. The Company’s initial focus is
on the treatment of primary and metastatic liver cancers. Delcath
recently concluded a Phase III metastatic melanoma study, and the
Company is currently conducting a multi–arm Phase II trial to
treat other liver cancers. The Company has not yet received FDA or
any foreign regulatory approval for commercial sale of its system.
For more information, please visit the Company’s website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides
a safe harbor for forward–looking statements made by the
Company or on its behalf. This news release contains
forward–looking statements, which are subject to certain
risks and uncert